/
Neurology
Neuropathy
70
Pipeline Programs↗
108
Active Trials↗
82
Companies Involved↗
Neuropathy is a moderately active landscape with 70 programs across 82 companies. The most active players are Argenx, Dianthus Therapeutics, GSK. 19 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical29
Phase 16
Phase 216
Phase 319
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
51 of 58 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 58 classified programs, each share of the total. Modality classified for 89% of 70 pipeline programs.
Analysis
Trial Status
505
clinical trials
Completed264 · 52%
Unknown status66 · 13%
Recruiting54 · 11%
Terminated46 · 9%
Not yet recruiting29 · 6%
Active, not recruiting22 · 4%
Other24 · 5%
Clinical Trials
Trial Activity
505 trials
Data Collection of Standard Care of Patients in the EMG Section
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT05041387·200 enrolled
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Recruiting·—·Phase 3·NCT07453888·272 enrolled
New Non-invasive Modalities for Assessing Retinal Structure and Function:Preliminary Investigation
Recruiting·—·Preclinical·NCT03475173·500 enrolled
Page 1 of 34
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)